TXB4-BC1

N/A

Report date: 2025/01/26 17:34:51

Base Information

Drug NameTXB4-BC1

Drug Alias Nameanti-transferrin receptor/anti-CD20 VNAR bispecific antibodies (Ossianix)anti-transferrin receptor/rituximab VNAR bispecific antibodies (Ossianix)TXB4-BC1

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Monoclonal antibody conjugateBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody conjugate

Mechanisms of ActionB-lymphocyte antigen CD20 inhibitorsTransferrin receptor protein 1 antagonists

TargetsTransferrin receptor protein 1B-lymphocyte antigen CD20

Therapy Area/IndicationsCentral Nervous System Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesUnited Kingdom

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesOssianix Inc

China Registration ClassN/A

Develop Information

Active CompaniesOssianix Inc

Inactive CompaniesN/A

Active IndicationsCentral Nervous System Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A